ECLS | Extracorporeal Membrane Oxygenation

Registry Dashboard of ECMO-Supported COVID-19 Patient Data

Thank you for helping ELSO disseminate information by entering your experience in the ELSO Registry as soon as ECMO is implanted - before the run is complete. Instructions for entering data in the Registry and COVID-19 addendum can be found on the Data Definitions page.

We recognize you cannot complete and submit the entire ELSO Registry case report form prior to completion of the ECMO run and discharge from the hospital, but we would still like to have the data you know now.

To address concerns about incomplete data we report three nested data sets to accommodate the fact that different patients will be at different stages of care (and thus have more or less incomplete data). Also when considering the data please understand that the data displayed is a real-time data stream and subject to change as more patient information is accrued and as centers update the ELSO Registry Case Report Form and the ELSO COVID-19 addendum.



COVID-19 Cases on ECMO in the ELSO Registry

Total COVID-19 Cases COVID-19
Confirmed Cases
12,386
Total counts of COVID-19 confirmed patients.

COVID-19 ECMO counts by ELSO Chapter

Still on ECMO Still Hospitalized at ELSO Center Total (n)
All ELSO 857 1,210 12,435
          North America 441 608 8,082
          Europe 212 296 2,551
          Asia Pacific 34 46 195
          Latin America 104 171 828
          SWAAC 66 89 779
Reports counts of ECMO-supported suspected or confirmed COVID-19 cases by ELSO Chapter

Filters affect the data shown in the tables below:

Region

Patient Age


Patients who initiated ECMO at
least 90 days ago
COVID-19
Confirmed
11,248
COVID-19
In-hospital Mortality
48%

Outcomes

Pre-ECMO Patient Factors

Patient-level summaries of COVID ECMO runs. All categorical variables are given as 'percentage (count)'
Total ARDS Cohort
Number cases 11248 8590
Age(years)
Median(IQR) 48(38,56) 48(38,56)
# observed 11248 8590
BMI, kg/m2
Median(IQR) 32(28,38) 33(28,38)
# observed 10558 8066
Sex
Male 69%(7797) 70%(6041)
Female 31%(3448) 30%(2547)
# observed 11245 8588
Race/Ethnicity
Black 11%(1268) 11%(934)
White (Non-Hispanic) 43%(4808) 43%(3662)
Asian 9%(972) 8%(682)
Mid East, N African 4%(483) 5%(418)
Other 3%(358) 3%(279)
Unknown 4%(470) 4%(362)
Multiple 4%(467) 5%(395)
Hispanic 22%(2422) 22%(1858)
# observed 11248 8590
Pre-ECMO Comorbidities
No comorbidity 24%(2731) 23%(1986)
Cancer 2%(172) 2%(130)
Pregnancy 4%(451) 4%(330)
Immunocompromised 4%(410) 4%(319)
Diabetes 25%(2836) 26%(2255)
Pre-existing heart disease 4%(397) 3%(242)
Pre-existing lung disease 4%(413) 4%(326)
Pre-existing renal insuff. 3%(304) 3%(228)
Frailty 1%(82) 1%(51)
Asthma 11%(1211) 11%(930)
BMI 52%(5803) 53%(4589)
Hypertension 32%(3627) 34%(2886)
# observed 11248 8590
Acute illness
ARDS 80%(9040) 100%(8590)
Acute heart failure 7%(744) 5%(390)
Myocarditis 2%(212) 1%(50)
Acute kidney injury 25%(2841) 26%(2275)
# observed 11248 8590
Pre-ECMO Cardiac Arrest
Yes 5%(572) 3%(245)
No 95%(10536) 97%(8235)
# observed 11108 8480
Pre-ECMO Co-Infection
No Co-infection 51%(5692) 48%(4104)
Bacterial pneumonia 43%(4875) 46%(3992)
Co-viral infection 9%(1043) 9%(756)
Blood stream infection 16%(1835) 18%(1551)
Urinary tract infection 7%(834) 8%(692)
# observed 11246 8588

Pre-ECMO Interventions

Support and therapies. All categorical variables are given as 'percentage (count)'
PreECLS PreECLS
Number cases 11248 8590
Noninvasive ventilation
Noninvasive ventilation prior to intubation 77%(8688) 80%(6854)
BiPAP 38%(4288) 40%(3454)
CPAP 14%(1540) 12%(1063)
HFNC 51%(5777) 55%(4704)
# observed 11246 8588
Pre-ECLS intubation (days)
Median(IQR) 3.0(0.8,6.0) 3.2(1.0,6.1)
# observed 9759 7465
Ventilator mode
Conventional 96%(9652) 97%(7542)
# observed 10008 7772
PEEP, cm H2O
Median(IQR) 14.0(10.0,16.0) 14.0(11.0,16.0)
# observed 9006 7083
PIP, cm H2O
Median(IQR) 33.0(30.0,38.0) 34.0(30.0,38.0)
# observed 7308 5669
FiO2
Median(IQR) 1.00(0.95,1.00) 1.00(1.00,1.00)
# observed 8984 6976
PaO2/FiO2
Median(IQR) 70(57,90) 70(57,89)
# observed 8788 6828
PCO2
Median(IQR) 61(50,75) 61(51,75)
# observed 9235 7140
Pre-ECMO Support
Prone positioning 55%(6130) 58%(4946)
# observed 11169 8530
Neuromuscular blockers 71%(7926) 74%(6336)
# observed 11170 8530
Inhaled pulmonary vasodilators 30%(3325) 32%(2765)
# observed 11169 8530
Any vasoactive support 57%(6386) 57%(4818)
# observed 11163 8525
Norepinephrine 51%(5699) 52%(4391)
# observed 11163 8525
Therapies, Immunomodulators
Any therapy 89%(9963) 92%(7864)
Glucocorticoids 78%(8794) 81%(6971)
IVIG 2%(242) 2%(141)
Anti-cytokine 23%(2557) 25%(2111)
Lopinavir/Ritonavir 2%(254) 2%(213)
JAK inhibition 2%(275) 3%(238)
Chloroquine/hydroxychloroquine 9%(971) 9%(782)
Remdesivir 49%(5546) 52%(4501)
# observed 11248 8590
Support type
Respiratory 95%(10681) 100%(8571)
Cardiac 4%(440) 0%(8)
ECPR 1%(127) 0%(11)
# observed 11248 8590

Patient Status & Complications

Outcomes
Total ARDS Cohort
Last known patient status
Discharged alive to home or acute rehabilitation 24%(2745) 24%(2048)
Discharged alive to long-term acute care or unspecified location 11%(1287) 12%(1055)
Discharged to another hospital 12%(1312) 11%(924)
Remain in the hospital (discharged from ICU) 0%(16) 0%(10)
Remain in the ICU 4%(433) 4%(319)
In-hospital death 48%(5455) 49%(4234)
Hours on ECMO 603 633
Tracheostomy 45%(4544) 48%(3738)
# observed 10050 7733
Select complications
Seizures 1%(87) 1%(66)
# observed 10962 8374
CNS infarction by US/CT/MRI 1%(152) 1%(100)
# observed 10962 8374
CNS hemorrhage by US/CT/MRI 7%(736) 7%(585)
# observed 10962 8374
Hemolysis 7%(822) 8%(660)
# observed 10962 8374
Oxygenator failure 19%(2123) 21%(1777)
# observed 10962 8374
Pump failure 2%(251) 2%(201)
# observed 10962 8374
Circuit change 13%(1417) 14%(1140)
# observed 10962 8374
Thrombosis/Clots in circuit component 4%(405) 4%(323)
# observed 10962 8374
Discharge location
Home 30%(1611) 30%(1215)
Transfer to LTAC or Rehab 5%(254) 6%(223)
Transfer to another hospital 25%(1312) 23%(924)
Other/Unknown 4%(239) 4%(152)
*N/A - Data elements with n<5 are not displayed.

ELSO Ownership, No Rights to Publication, Disclaimer

The Dashboard content has been compiled and reported from a variety of sources, is not independently verified by ELSO, and is subject to change without notice. ELSO and its authorized agents and contractors make no representations or warranties about the quality, content, completeness, suitability, adequacy, sequence, accuracy, or timeliness of such content. ELSO disclaims any responsibility for any inaccuracy, whether by inclusion or omission, on the Dashboard or the Site, and disclaims any responsibility for subsequent change or withdrawal of data shown on the Dashboard or the Site, which is subject to alteration without notice. ELSO disclaims any and all warranties regarding this information and all liability whatsoever relating thereto. Any person who uses information obtained from this Dashboard does so at his or her own risk.

The Dashboard is provided as a public service to facilitate real-time sharing of information during the COVID-19 crisis for educational purposes only by health practitioners. ELSO owns the compilation of all data, and its use or publication by any third party is strictly forbidden. Publication or representation of this information as if it were statistically significant or part of a scientific study is irresponsible and misleading.

The tables are consistent with the Lancet Publication article but the data presented here is real time

Barbaro RP, MacLaren G, Boonstra PS, Iwashyna TJ, Slutsky AS, Fan E, Bartlett RH, Tonna JE, Hyslop R, Fanning JJ, Rycus PT, Hyer SJ, Anders MM, Agerstrand CL, Hryniewicz K, Diaz R, Lorusso R, Combes A, Brodie D, the Extracorporeal Life Support Organization. Extracorporeal Membrane Oxygenation Support in COVID-19: The Registry Report from the Extracorporeal Life Support Organization. Lancet. 2020; [In Press].

We’ve updated our Privacy Policy. By continuing to use this Service, you acknowledge you’ve read the updated Privacy Policy.